2019-2021 Drug Discovery for Neurodegeneration Conferences

2019-2021 神经退行性疾病药物发现会议

• 批准号: 10180809
• 负责人: Howard M. Fillit
• 金额: $ 7.49万
• 依托单位: ALZHEIMER'S DRUG DISCOVERY FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-01-15 至 2022-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10180809
• 关键词: Academia; Address; Advanced Development; Advisory Committees; Aging; Alzheimer' s Disease; Area; Basic Science; Biologic Development; Case Study; Clinical Trials; Collaborations; Communities; Development; Discipline; Disease; District of Columbia; Drug Industry; Evaluation; Fostering; Foundations; Funding; Goals; Grant; Industry; Infrastructure; Innovative Therapy; International; Knowledge; Lead; Learning; Mentors; Minority; Multiple Sclerosis; NIH Program Announcements; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Participant; Prevention; Process; Research; Research Contracts; Research Personnel; Resource Sharing; Resources; Schedule; Science; Scientist; Surveys; Testing; Training; Translating; Translational Research; U-Series Cooperative Agreements; United States National Institutes of Health; Update; Woman; acronyms; career; clinical candidate; drug development; drug discovery; education resources; effective therapy; graduate student; meetings; multidisciplinary; nervous system disorder; new therapeutic target; next generation; novel; novel therapeutics; outreach; posters; pre-clinical research; prevent; programs; public-private partnership; quantum; skills; small molecule; symposium; therapy development; trend; web portal; web site

PROJECT SUMMARY/ABSTRACT There is a well-documented knowledge and resource gap in translating basic research into novel therapeutics. Outside of the pharmaceutical industry, there are very few opportunities for the next generation of scientific leaders to learn about the drug discovery and development process in general, and particularly for neurodegenerative diseases. To meet this need, the Alzheimer’s Drug Discovery Foundation (ADDF) developed the annual Drug Discovery for Neurodegeneration (DDND) conference, which has reached 1,698 participants since its inception in 2007. The ADDF requests a U13 Cooperative Agreement conference grant for three years of support for its DDND conference, scheduled for the Southern CA area in March 2019; Miami, FL or Washington DC in March 2020; and the Southern CA area in March 2021. The goals of these didactic conferences are consistent with the initiatives set forth at the NIH’s 2012 and 2015 Alzheimer’s Disease Research Summits: to bridge the knowledge gap in drug discovery for neurodegenerative diseases; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; and to provide networking opportunities for these scientists to exchange ideas and resources. These conferences will provide participants with fundamental knowledge and resources on developing new drugs to treat and prevent neurodegenerative diseases, and will address the challenges associated with the following sub-topics: Embarking on a Drug Discovery Campaign; Drug Discovery: From Lead to Clinical Candidate; Accelerating Therapies into Clinical Trials; Strategies for CNS Targets: Case Study Examples; and Building the Infrastructure to Commercialize Science into Products. Discussions will include relevant examples focused on small molecule and biologic development for neurodegenerative diseases. Sessions will consist of 20-minute presentations with 10-minute Q&As, and the program will include sessions for networking, mentoring, poster sessions presented by young investigators, and an early investigator career panel. With respect to public-private partnerships, the ADDF will invite 21 internationally recognized scientists from academia, industry, and the NIH to serve as chairs or speakers. We have assembled a Scientific Advisory Committee that has agreed to participate for the next three years to assist in the development of the conferences. It is anticipated that these conferences will serve 150 scientists annually from diverse backgrounds, including women, minorities, young/junior investigators, and graduate students.

项目概要/摘要 在将基础研究转化为新颖的过程中存在有据可查的知识和资源缺口 在制药行业之外，治疗学的机会很少。 下一代科学领袖了解药物发现和开发过程 一般来说，特别是针对神经退行性疾病，为了满足这种需求，阿尔茨海默氏症。 药物发现基金会 (ADDF) 制定了年度药物发现 神经退行性疾病 (DDND) 会议自召开以来已有 1,698 名与会者 ADDF 于 2007 年成立。ADDF 请求 U13 合作协议会议拨款，以资助三名学生 多年来对定于 2019 年 3 月在加利福尼亚州南部地区举行的 DDND 会议的支持； 2020 年 3 月在佛罗里达州迈阿密或华盛顿特区；2021 年 3 月在加利福尼亚州南部地区。 这些教学会议的目标与 NIH 提出的倡议一致 2012年和2015年阿尔茨海默病研究峰会：弥合药物知识差距 神经退行性疾病的发现；汇集跨学科科学家 激发结合技能和学科的新方法，并提供交流机会； 让这些科学家交流思想和资源。 这些会议将提供以下方面的基础知识和资源： 开发治疗和预防神经退行性疾病的新药，并将解决 与以下子主题相关的挑战： 着手药物发现 活动；药物发现：从先导药物到临床候选药物； 临床试验；中枢神经系统靶点策略：案例研究实例和构建 将科学商业化为产品的基础设施将包括相关内容。 例子集中于神经退行性疾病的小分子和生物开发。 会议将包括 20 分钟的演讲和 10 分钟的问答，并且该计划将 包括由年轻研究人员举办的网络会议、指导会议、海报会议、 以及早期研究者职业小组。 在公私合作方面，ADDF将邀请21个国际公认的机构 来自学术界、工业界和美国国立卫生研究院的科学家担任主席或发言人。 组建了一个科学咨询委员会，并同意参加接下来的三年 预计这些会议将花费数年时间协助会议的发展。 每年为 150 名来自不同背景的科学家提供服务，包括女性、少数族裔、 年轻/初级研究人员和研究生。